A fingertip test that could reveal hidden danger in sepsis

NCT ID NCT07774962

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study looks at whether a simple bedside check called capillary refill time (pressing on a fingernail to see how fast color returns) can be combined with a blood test to spot a hidden problem in septic shock. Sometimes blood flow to organs seems normal, but tissues are still not getting enough oxygen. The study will follow 100 adults with septic shock, measuring these two markers at several time points, to see if a mismatch between them is linked to higher risk of death within 28 days. No extra procedures are involved—all measurements are part of routine care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Capillary refill time measurement and oxygen extraction ratio calculation from routine blood gases
What this could lead to
If this works, it could help doctors identify septic shock patients who need more tailored treatment, potentially improving survival.
What could go wrong
This is a small, single-center observational study, so it can only show associations, not cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive adult patients (≥18 years) admitted to a single-center intensive care unit and diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline, who already have a central venous catheter and an arterial line in place as part of their clinical care. Patients are enrolled from all admission sources (emergency department, ward, operating room, or external referral) and followed prospectively while receiving standard treatment. Patients with active bleeding, ongoing ECMO, conditions that make capillary refill time measurement unreliable (e.g., Raynaud phenomenon or significant peripheral vascular disease), death within the first 6 hours, or inability to obtain hour-6 CRT or blood gas measurements are not included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline * Presence of both a central venous catheter and an arterial line Exclusion Criteria: * Active bleeding * Ongoing extracorporeal membrane oxygenation (ECMO) * Raynaud phenomenon or significant peripheral vascular disease that makes capillary refill time measurement unreliable (e.g., critical ischemia, amputation, digital ulcer/necrosis, or inability to measure on the right index finger) * Death within the first 6 hours * Inability to obtain hour-6 CRT or blood gas (phenotyping not possible)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Basaksehir Cam and Sakura City Hospital

    RECRUITING

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.